Great West Life Assurance Co. Can maintained its position in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,644 shares of the biotechnology company’s stock at the end of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in ZIOPHARM Oncology were worth $109,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Creative Planning raised its holdings in ZIOPHARM Oncology by 5.2% in the second quarter. Creative Planning now owns 60,863 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 3,000 shares in the last quarter. Teachers Advisors LLC raised its holdings in ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after acquiring an additional 3,699 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in ZIOPHARM Oncology by 4.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 88,717 shares of the biotechnology company’s stock valued at $562,000 after acquiring an additional 3,886 shares in the last quarter. American International Group Inc. raised its holdings in ZIOPHARM Oncology by 7.1% in the first quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 4,951 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 7,875 shares in the last quarter. 41.94% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/20/great-west-life-assurance-co-can-has-109000-stake-in-ziopharm-oncology-inc-ziop.html.

Several research firms recently issued reports on ZIOP. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $13.17.

Shares of ZIOPHARM Oncology Inc (ZIOP) opened at 6.18 on Wednesday. The firm’s 50-day moving average is $5.85 and its 200 day moving average is $6.25. ZIOPHARM Oncology Inc has a 1-year low of $4.84 and a 1-year high of $7.88. The company’s market cap is $869.11 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period in the prior year, the company posted ($1.01) earnings per share. The firm’s revenue was down 5.9% compared to the same quarter last year. Equities analysts expect that ZIOPHARM Oncology Inc will post ($0.56) EPS for the current fiscal year.

ZIOPHARM Oncology Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.